Результаты поиска

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.

BackgroundBispecific antibody (BsAb)-based cancer immunotherapy has provided new avenues for the treatment of various malignancies. The approval of Blinatumomab has encouraged further investigation into these treatments, and a series of preclinical and clinical trials have been conducted, together with the publication of numerous articles. Here, the knowledge structure of BsAb-based cancer immunotherapy is summarized using bibliometric analysis to provide in-depth insight into current research trends and foci.MethodsThe studies included in the bibliometric analysis of BsAbs in cancer immunothe

Customer-centric product presentations for monoclonal antibodies.

Delivering customer-centric product presentations for biotherapeutics, such as monoclonal antibodies (mAbs), represents a long-standing and paramount area of engagement for pharmaceutical scientists. Activities include improving experience with the dosing procedure, reducing drug administration-related expenditures, and ultimately shifting parenteral treatments outside of a controlled healthcare institutional setting. In times of increasingly cost-constrained markets and reinforced with the coronavirus pandemic, this discipline of "Product Optimization" in healthcare has gained momentum and ch

Бремя множественной миеломы в азиатских странах 1990 в адрес 2021 и прогнозирование тенденций 2050:: анализ, основанный на Глобальном исследовании бремени болезней 2021.

Множественная миелома (ММ) создает растущую угрозу для здоровья населения во всем мире, причем региональные различия в бремени болезней становятся все более заметными. Являясь самым густонаселенным континентом, Азия переживает быстрые демографические и социально-экономические изменения и играет решающую роль в формировании эволюционной траектории глобального бремени ММ. Цель этого исследования заключается в оценке бремени болезней, связанных с множественной миеломой в азиатских странах. 1990 в адрес 2021Данные этого исследования были получены на основе исследования глобального бремени болезней

CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting.

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic acti

Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023.

BackgroundAlthough racially and ethnically minoritized populations are less likely to participate in cancer trials, it is unknown whether social determinants of health (SDOH) explain these inequities. Here we identify SDOH factors that contribute to racial and ethnic inequities in clinical trial participation among patients with 22 common cancers.MethodsThis retrospective cohort study used electronic health record data (2011-2023) linked to neighborhood (US Census tract) data from multiple sources. Patients were followed from diagnosis to clinical study drug receipt (proxy for trial participat

Clinical Profile and Outcomes of Patients With Hypercalcemia in an Indian Tertiary Care Center.

Hypercalcemia is a complex medical condition characterized by elevated levels of serum calcium (>10.5 mg/dL) in the bloodstream, often arising from various underlying etiologies. This condition presents a significant clinical challenge due to its diverse clinical manifestations and potential for serious complications. Profiling and understanding hypercalcemia is essential for accurate diagnosis, appropriate management, and improved patient outcomes. In this study, we delve into the comprehensive profiling of hypercalcemia, encompassing its epidemiology, pathophysiology, clinical presentation,

First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.

Lessons learnedResults are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease.MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity.Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline.MBC-11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development.BackgroundMBC-11 is a first-in-class conju

Использование анализа периода для своевременного представления серийных данных о длительном выживании пациентов с гематологическими отклонениями из Тайжоу, Восточный Китай.

В то время как диагностические и терапевтические новшества значительно улучшили прогноз гематологических магнентов (ГМ), всеобъемлющих данных об их выживаемости в Китае по-прежнему недостаточно. Это исследование было направлено на изучение вопроса о том, как в долгосрочной перспективе выживают обычные ТМ у китайского населения. МЕТОДЫ: В рамках данного исследования, посвященного населению, мы проанализировали данные, полученные от nine - реестры раковых заболеваний в Тайжоу, восточный Китай, с охватом пациентов в возрасте ≥15 годы, диагностированные с помощью ТМ между 2009 и 2023. Периодически

Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma.

A key treatment for patients with multiple myeloma is high-dose melphalan followed by autologous stem cell transplant (ASCT). It can provide a deep response with long-term remission. However, some patients progress quickly, and it is not clear why. In this study, we performed single-cell RNA and T-cell receptor sequencing of the immune microenvironment of 40 patients before and after ASCT to determine if differences in the immune composition could define those who would progress. Clear differences in cell populations were identified in progressors, including increased T-cell infiltration, decr

Профилактические преимущества фармакодинамики GLP-1 Агонисты рецепторов и ингибиторы SGLT2 по нейродегенеративным заболеваниям: данные сетевого метаанализа.

Глукагон, похожий на глюкагон peptide-1 (В тыс.GLP-1) рецепторные агонисты и котранспортер с глюкозой натрия 2 (SGLT2) ингибиторы представляют собой новое поколение антигипергликемических агентов, которые действуют с помощью механизмов, отличных от традиционных методов лечения диабета. Помимо своего метаболического воздействия, эти препараты продемонстрировали нейрозащитные свойства в ходе предклинических исследований. Хотя в ходе клинических испытаний изучался их терапевтический потенциал в установленных нейродегенеративных условиях, их роль в профилактике заболеваний остается неясной. Мы про

Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.

In breast cancer, lipid metabolic alterations have been recognized as potential oncogenic stimuli that may promote malignancy. To investigate whether the oncogenic nature of lipogenesis closely depends on the overexpression of HER2 protooncogene, the normal breast cell line, HB4a, was transfected with HER2 cDNA to obtain HER2-overexpressing HB4aC5.2 cells. Both cell lines were treated with trastuzumab and docosahexaenoic acid. HER2 overexpression was accompanied by an increase in the expression of lipogenic genes involved in uptake (CD36), transport (FABP4), and storage (DGAT) of exogenous fat

Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications.

The insufficient and unspecific target of traditional therapeutic approaches in cancer treatment often leads to therapy resistance and cancer recurrence. Over the past decades, accumulating discoveries about stem cell biology have provided new potential approaches to cure cancer patients. Stem cells possess unique biological actions, including self-renewal, directional migration, differentiation, and modulatory effects on other cells, which can be utilized as regenerative medicine, therapeutic carriers, drug targeting, and generation of immune cells. In this review, we emphasize the mechanisms

Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Italian onco-haematological patients' preferences in bad news communication: a preliminary investigation.

BackgroundThe manner in which bad news is communicated in oncological contexts can affect patients' engagement, their coping strategies and therapeutic compliance. Although this topic has been broadly investigated since the nineties, to the best of our knowledge, little has been written about Italian patients' experiences and preferences concerning what the oncologists should disclose and how they should intimate patients about their health conditions in different stages of oncological disease.MethodsIn an attempt to fill this gap, an online self-report questionnaire was administered to a samp

Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

In Primary Myelofibrosis (PMF), megakaryocyte dysplasia/hyperplasia determines the release of inflammatory cytokines that, in turn, stimulate stromal cells and induce bone marrow fibrosis. The pathogenic mechanism and the cells responsible for progression to bone marrow fibrosis in PMF are not completely understood. This review article aims to provide an overview of the crucial role of megakaryocytes in myelofibrosis by discussing the role and the altered secretion of megakaryocyte-derived soluble factors, enzymes and extracellular matrices that are known to induce bone marrow fibrosis.

Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023.

BackgroundMultiple myeloma (MM) is a malignant plasma cell disorder associated with substantial mortality and long-term disability. With rapid population aging in China, its disease burden may be increasing, yet comprehensive long-term assessments remain limited.MethodsUsing data from the Global Burden of Disease Study 2023, we evaluated trends in prevalence, incidence, deaths, and disability-adjusted life years (DALYs) of MM in China from 1990 to 2023. Age-standardized rates were analyzed using Joinpoint regression to estimate temporal trends.ResultsBetween 1990 and 2023, prevalence, incidenc

Иммунотерапия при помощи модуляции кишечного микробиота в множестве склерозов и ассоциации с диетологической и клинической реакцией - эффект диметилфуматовой терапии.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Накопление данных подтверждает ту роль, которую микробиота играет в здравоохранении и болезнях, в том числе в многократном склерозе (МС). Как наркотики MS влияют на микробиоту и является ли это частью их способа действия, пока неизвестно. ЦЕЛИ: Оценка воздействия диметилфумарата (ДМП) на кишечник микробиота и того, связана ли микробиота с клинической реакцией или неблагоприятными явлениями (АЭ) с ДМФ или с диетой. DESIGN: когортное исследование наблюдений, в котором микробиота 45 больные с повторной эмиссией MS до начала работы DMF и после этого 6 месяцев психотерапии ДМ

Investigation of differences between chronological and vascular age in persons with multiple sclerosis.

OBJECTIVE: To determine vascular age (VA) in a cohort of persons with multiple sclerosis (PwMS) in Belgrade, Serbia, and to assess the difference between chronological age (CA) and VA, in this population. MATERIAL AND METHODS: A case-control study was conducted at the Clinic of Neurology, University Clinical Center of Serbia in Belgrade. Study participants (n = 274) were recruited during regular outpatient visits. Demographic and clinical characteristics including the presence of CVD comorbidities of PwMS were collected. Data were obtained using a questionnaire, designed and adapted for the st

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma.

This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6.75 mg/m2 on days 1-4, once-weekly dose of oral cyclophosphamide 300 mg/m2 and dexamethasone 20 mg/m2 on days 1-4 and days 15-18. Each cycle was repeated every 28 days. The median age of the patients was 66 years and the MCD regimen was initi

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

BackgroundMyeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefit from antibiotic prophylaxis to prevent infection, and to investigate the effect on antibiotic-resistant organism carriage and health care-associated infections in patients with newly diagnosed myeloma.MethodsTEAMM was a prospective, multicentre, double-blind, placebo-controlled randomise

Совпадение в полном тексте источника
… The password-protected list was sent to the drug packaging company who put the active drugs or placebo in correctly labelled packs. This list was then used to build the bespoke randomisation and drug inventory system. …